Journal article
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
TM Shekhar, IJG Burvenich, MA Harris, A Rigopoulos, D Zanker, A Spurling, BS Parker, CR Walkley, AM Scott, CJ Hawkins
BMC Cancer | BMC | Published : 2019
Open access
Abstract
Background: Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. "Smac mimetics" (also known as "IAP antagonists") are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas were efficiently sensitized by physiologically achievable concentrations of some Smac mimetics (including GDC-0152 and LCL161) to killing by the inflammatory cytokine TNFα in vitro, but survived exposure to Smac mimetics as sole agents. Methods: Nude mice were subcutaneously or intramuscularly implanted with luciferase-expressing murine 1029H or human KRIB osteosarcoma cells. The impacts of treatment with G..
View full abstractGrants
Funding Acknowledgements
This study was funded by a grant from The Kids' Cancer Project, a Sarcoma Research Grant from the GPA Andrew Ursini Charitable Fund and the Australasian Sarcoma Study Group, and a Grant-in-Aid from the Cancer Council Victoria. These organizations financed the work but played no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.